Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 11.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,576 shares of the biotechnology company’s stock after selling 449 shares during the period. ProShare Advisors LLC’s holdings in Ascendis Pharma A/S were worth $488,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ASND. Private Ocean LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter worth $36,000. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after buying an additional 102 shares during the period. Barometer Capital Management Inc. purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $126,000. Bessemer Group Inc. increased its position in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 332 shares during the period. Finally, Searle & CO. purchased a new stake in Ascendis Pharma A/S during the 2nd quarter valued at approximately $205,000.

Ascendis Pharma A/S Price Performance

ASND opened at $149.31 on Tuesday. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The stock has a market cap of $8.69 billion, a P/E ratio of -15.54 and a beta of 0.63. The stock’s 50 day simple moving average is $134.65 and its 200 day simple moving average is $136.36.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. Research analysts expect that Ascendis Pharma A/S will post -7.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ASND shares. Citigroup boosted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Jefferies Financial Group boosted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Finally, Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $195.00.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.